Atherectomy Devices Market Opportunities: Rising Vascular Disease Burden Opens New Growth Avenues

Author : Warner White | Published On : 23 Sep 2026

The Atherectomy Devices Market is valued at US$ 1.08 Billion in 2025 and is projected to reach US$ 1.96 Billion by 2034, expanding at a CAGR of 6.85% during 2026–2034. The market is expanding as healthcare providers increasingly adopt minimally invasive approaches for treating peripheral and coronary artery disease. Atherectomy devices help remove or modify plaque within narrowed arteries, supporting vessel preparation and improving the effectiveness of subsequent interventional procedures. Rising cardiovascular disease burden, increasing use of endovascular interventions, and technological advances in plaque-modification systems are supporting market growth.

What is driving the market?

The growing prevalence of peripheral artery disease, increasing adoption of minimally invasive vascular procedures, and demand for effective plaque modification are major growth drivers. As the global burden of atherosclerotic disease increases, physicians are seeking technologies that can address heavily calcified or complex lesions while minimizing surgical trauma. Atherectomy can be used to modify plaque before balloon angioplasty, drug-coated balloon treatment, or stent placement, making it an important technology within contemporary endovascular treatment strategies.

Technological development is further broadening the applications of atherectomy systems. Directional, orbital, rotational, and laser-based technologies provide different mechanisms for removing or modifying arterial plaque. Improvements in catheter design, device deliverability, imaging integration, and lesion-crossing capabilities are helping physicians manage increasingly complex vascular anatomy.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPHE100001272

Which region leads?

North America represents a significant regional market for atherectomy devices, supported by advanced interventional cardiology infrastructure, high adoption of minimally invasive vascular procedures, and established healthcare facilities. The US has a large base of vascular specialists and interventional cardiologists, while continued investment in advanced catheter-based technologies supports the adoption of plaque-modification devices.

The region’s demand is also supported by the increasing use of endovascular procedures for peripheral artery disease and complex arterial lesions. Hospitals and ambulatory treatment centers are increasingly focused on technologies that can improve procedural efficiency and expand treatment options for patients who may be unsuitable for conventional approaches.

Europe also remains an important market, supported by established healthcare systems, specialist vascular centers, and increasing utilization of minimally invasive interventions. Meanwhile, Asia Pacific presents significant expansion opportunities as healthcare infrastructure improves, cardiovascular disease awareness increases, and advanced interventional technologies become more accessible. Growing healthcare expenditure in countries such as China and India is creating additional opportunities for manufacturers to expand the availability of atherectomy technologies.

Which segment leads?

Atherectomy technologies designed for effective plaque modification represent a core segment of the market, with device selection increasingly influenced by lesion characteristics, plaque composition, vessel anatomy, and procedural objectives. Different atherectomy approaches are designed to address specific clinical requirements, including heavily calcified lesions and plaque located in peripheral arteries.

Orbital, rotational, directional, and laser atherectomy technologies each provide distinct mechanisms for plaque treatment. Rotational systems use a high-speed rotating component to modify plaque, while orbital technologies create an orbital pathway that can treat calcified lesions. Directional systems allow targeted plaque removal, and laser systems use laser energy to modify obstructive material.

Peripheral artery interventions represent an important application area because complex and calcified lesions can make conventional balloon angioplasty more challenging. Atherectomy can support vessel preparation before other endovascular therapies, creating opportunities for technologies capable of improving lesion compliance and facilitating subsequent treatment.

Which companies are prominent?

The report identifies B. Braun Melsungen AG, Koninklijke Philips N.V., Cardinal Health, Medtronic, Terumo Corporation, C. R. Bard, Inc., Minnetronix, Inc., Avinger, Straub Medical AG, Biomerics, Abbott, RA Medical Systems, and Boston Scientific Corporation as prominent market participants.

These companies compete across atherectomy systems, catheter technologies, vascular intervention platforms, and complementary endovascular products. Competitive differentiation increasingly depends on device performance, procedural control, ease of use, lesion-crossing capability, safety characteristics, and compatibility with other interventional technologies.

Product development is also focused on improving deliverability and expanding the types of lesions that can be treated through minimally invasive procedures. Companies are investing in catheter engineering and procedural technologies that can provide physicians with greater flexibility when treating complex peripheral and coronary vascular disease.

The competitive landscape therefore extends beyond individual atherectomy devices. Manufacturers with broader portfolios of balloons, stents, guidewires, imaging technologies, and other interventional products can integrate atherectomy into more comprehensive vascular treatment pathways.

What is changing in 2026?

The market is moving toward more sophisticated plaque-modification technologies designed to support complex endovascular procedures. Physicians are increasingly focused on vessel preparation, particularly when calcification or other plaque characteristics may limit the effectiveness of conventional balloon-based treatment.

Advances in catheter engineering are supporting smaller profiles, improved navigation, and greater procedural control. Integration with imaging and other interventional technologies is also becoming increasingly important as physicians seek better information about lesion morphology and treatment response.

Another important development is the increasing focus on personalized procedural strategies. Rather than relying on a single treatment approach, physicians can select plaque-modification technologies according to lesion location, severity, morphology, vessel size, and the intended downstream intervention. This creates opportunities for manufacturers to develop systems tailored to specific clinical scenarios.

What are the major investment opportunities?

The strongest opportunities lie in advanced plaque-modification systems, peripheral vascular interventions, next-generation catheter technologies, and technologies designed for complex calcified lesions. As the use of minimally invasive vascular procedures expands, manufacturers capable of improving procedural efficiency and device navigation can address growing clinical demand.

Investment opportunities also exist in low-profile atherectomy systems, improved lesion-crossing technologies, imaging-assisted interventions, and integrated vascular treatment platforms. These technologies can help address procedural challenges associated with complex anatomy and heavily calcified lesions.

Asia Pacific offers additional expansion potential as healthcare infrastructure develops and access to advanced cardiovascular interventions improves. Manufacturers entering these markets may benefit from partnerships with hospitals, specialist vascular centers, and regional healthcare providers.

Long-term opportunities will depend on clinical evidence, physician adoption, reimbursement conditions, device economics, and the ability to demonstrate meaningful procedural value. Companies that combine technological innovation with reliable performance, ease of use, and broad clinical applicability can strengthen their position as endovascular treatment continues to evolve.

Related Reports:

Hip Implants Market Size, Share & Demand by 2034

Knee Reconstruction Market Trends, Size & Growth by 2034

About Us

The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.

Contact Us

Contact Person: Ankit Mathur

Phone: +1-646-491-9876

E-mail : [email protected]